We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Caribou Biosciences Inc | NASDAQ:CRBU | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14 | -7.95% | 1.62 | 1.62 | 1.63 | 1.79 | 1.615 | 1.77 | 1,566,592 | 20:53:24 |
From Jun 2023 to Jun 2024
By Ben Glickman
Shares of Caribou Biosciences rose after the company's lymphoma trial design was approved by the Food and Drug Administration.
The stock was up 4.1% to $5.88 in after-hours trading following a 1.9% drop at Tuesday's close. Shares are down 10% this year.
The Berkeley, Calif.-based gene-editing pharmaceutical company said it had received feedback from the FDA on its Phase 3 trial for CB-010, a treatment for large B cell lymphoma.
The company plans to initiate its Phase 3 trial by the end of 2024.
The trial design includes platinum-based immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation.
Chief Executive Rachel Haurwitz said the FDA feedback was "an important step in advancing our lead therapy."
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 12, 2023 18:11 ET (23:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Caribou Biosciences Chart |
1 Month Caribou Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
